# Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

> **NCT07690891** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 30 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Venetoclax
- **DRUG:** Obinutuzumab

## Key facts

- **NCT ID:** NCT07690891
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-12-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07690891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07690891, "Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07690891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*